I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
ORCIDGoogle ScholarLinkedInGitHub
A source-typed audit of revumenib and ziftomenib separates calibration, prediction and clinical evidence. Reduced-model calculations examine joint endpoint tolerances, cross-drug borrowing and mechanistic ambiguity without claiming independent clinical validation.
Hill fits, conditional profiles and technical redo comparisons distinguish usable transitions from unidentified EC50 values in a selected three-drug, six-cell-line dataset. Technical precision is not biological reproducibility.
A fixed-effect plasma/PBMC subsystem from a published clinical model is implemented independently. Equal doses give equal plasma AUC, while PBMC AUC differences are determined by a categorical formation-clearance assumption. Constant-formation and tail scenarios clarify limits; no tumor, clinical benefit, safety or regimen recommendation is inferred.